Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Nicola Curtis"'
Autor:
Susan Ashton, Simon T. Barry, Rajesh Odedra, Nicola Curtis, Shenghua Wen, Nicolas Floc'h, Jacqueline Caddy, James Pilling, Paula Taylor, Dawn Trueman, Emily Harris, Maureen Hattersley, Vivien Jacobs, Nicola Derbyshire, Elizabeth Janet Pease, Kim Maratea
Publikováno v:
Molecular Cancer Therapeutics. 16:1031-1040
Barasertib (AZD1152), a highly potent and selective aurora kinase B inhibitor, gave promising clinical activity in elderly acute myeloid leukemia (AML) patients. However, clinical utility was limited by the requirement for a 7-day infusion. Here we a
Autor:
Stephen Green, Armelle Logie, Nichola Whalley, Nicola Curtis, Kate Byth, Haihong Zhong, Clare Murray, Mike Firth, Lorna Hopcroft, Lorraine Mooney, Filippos Michopoulos, Paul D. Smith, Amanda Benjamin, Mitchell Revill, Susan E. Critchlow
Publikováno v:
Oncotarget
// Nicola J. Curtis 1 , Lorraine Mooney 1 , Lorna Hopcroft 2 , Filippos Michopoulos 1 , Nichola Whalley 2 , Haihong Zhong 3 , Clare Murray 4,6 , Armelle Logie 1 , Mitchell Revill 1 , Kate F. Byth 5 , Amanda D. Benjamin 4 , Mike A. Firth 1 , Stephen G
Autor:
Susan Ashton, Shenghua Wen, Simon T. Barry, Larissa S. Carnevalli, Paula Taylor, Kim Maratea, Emily Harris, Lucy H. Young, A. Hughes, Nicolas Floc'h, Maureen Hattersley, James Pilling, Elizabeth Janet Pease, Nicola Curtis, Douglas Ferguson
Publikováno v:
Molecular cancer therapeutics. 18(5)
Barasertib (AZD1152), a pro-drug of the highly potent and selective Aurora B kinase inhibitor AZD2811, showed promising clinical activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients administered as a 4-day infusion. To impro
Autor:
Ian M. Hardern, Jarrod Walsh, Ed Wheatley, Jon Winter-Holt, Sarita Maman, Judit E. Debreczeni, Graeme Walker, Susan E. Critchlow, Gareth M. Davies, Nicola J. Evans, Richard A. Ward, Neil P. Jones, Sheila B. McLoughlin, Andrew Peter Thomas, Neil Bennett, Geoff Holdgate, Nicola Curtis, Stephen A. St-Gallay, Lindsey Leach, Laurent Rigoreau, Andrew P. Turnbull, Marian Preston
Publikováno v:
SLAS discovery : advancing life sciences RD. 23(1)
A high-throughput screen (HTS) of human 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) resulted in several series of compounds with the potential for further optimization. Informatics was used to identify active chemotypes with lead-l
Autor:
Scott G. Lamont, James M. Smith, Joanna Brookfield, Edward R. Wheatley, Steve St-Gallay, Laurent Rigoreau, Sébastien L. Degorce, Jon Winter, Craig S. Donald, Scott Boyd, Julie K. Stock, Sam D. Groombridge, Philip Hopcroft, Nicola J. Evans, Iain A. Cumming, Nicola Curtis, Andrew P. Turnbull, Susan E. Critchlow, Judit E. Debreczeni, Sheila B. McLoughlin, Hilary J. Lewis, Philip MacFaull, Jonathan Wingfield, Neil P. Jones, Jason Grant Kettle
Publikováno v:
Journal of medicinal chemistry. 58(8)
A weak screening hit with suboptimal physicochemical properties was optimized against PFKFB3 kinase using critical structure-guided insights. The resulting compounds demonstrated high selectivity over related PFKFB isoforms and modulation of the targ
Publikováno v:
Antimicrobial agents and chemotherapy. 54(10)
A mariner transposon bank was used to identify loci that contribute to the innate resistance of Listeria monocytogenes to the lantibiotic nisin. In addition to highlighting the importance of a number of loci previously associated with nisin resistanc
Autor:
Thierry Dorval, Susan Ashton, James Pilling, Simon T. Barry, Philip J. Jewsbury, Nicola Curtis, Paula Taylor, Jeff Hrkach
Publikováno v:
Cancer Research. 75:3102-3102
Inhibitors of the Aurora Kinases have been developed to treat both liquid and solid tumours. The prodrug AZD1152 is an inhibitor of Aurora kinase B that is clinically active in acute myeloid leukaemia. Despite this clinical proof-of-concept, the broa
Autor:
Liang Xie, Jingchuan Zhang, Lorraine Mooney, Nicola Curtis, De-Hua Yu, Haihong Zhong, Clare Murray, Paul D. Smith, Nicky Whalley, Armelle Logie, Lorna Hopcroft, Susan E. Critchlow, Mitchell Revill
Publikováno v:
Cancer Research. 72:3224-3224
Introduction - The metabolic phenotype of tumours (relative to most normal tissues) is shifted from oxidative phosphorylation to aerobic (Warburg Effect) or anaerobic glycolysis. This enables tumours to meet their energetic and biosynthetic demands e